Tesfaye M, Savoldo B
Curr Oncol Rep. 2018; 20(9):73.
PMID: 30069644
PMC: 6386156.
DOI: 10.1007/s11912-018-0715-9.
Smith C, Khanna R
Immunol Cell Biol. 2016; 95(4):364-371.
PMID: 27999434
DOI: 10.1038/icb.2016.127.
Young L, Yap L, Murray P
Nat Rev Cancer. 2016; 16(12):789-802.
PMID: 27687982
DOI: 10.1038/nrc.2016.92.
Snider C, Cole S, Chelimo K, Sumba P, MacDonald P, John C
PLoS One. 2012; 7(3):e31753.
PMID: 22427806
PMC: 3299627.
DOI: 10.1371/journal.pone.0031753.
Futagbi G, Welbeck J, Tetteh J, Hviid L, Akanmori B
Malar J. 2007; 6:69.
PMID: 17521425
PMC: 1894981.
DOI: 10.1186/1475-2875-6-69.
The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue.
Fogg M, Kaur A, Cho Y, Wang F
J Virol. 2005; 79(20):12681-91.
PMID: 16188971
PMC: 1235856.
DOI: 10.1128/JVI.79.20.12681-12691.2005.
Adoptive immunotherapy of feline immunodeficiency virus with autologous ex vivo-stimulated lymphoid cells modulates virus and T-cell subsets in blood.
Flynn J, Pistello M, Isola P, Zaccaro L, del Santo B, Ricci E
Clin Diagn Lab Immunol. 2005; 12(6):736-45.
PMID: 15939748
PMC: 1151978.
DOI: 10.1128/CDLI.12.6.736-745.2005.
Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.
Gudgeon N, Taylor G, Long H, Haigh T, Rickinson A
J Virol. 2005; 79(9):5477-88.
PMID: 15827162
PMC: 1082738.
DOI: 10.1128/JVI.79.9.5477-5488.2005.
Potential selection of LMP1 variants in nasopharyngeal carcinoma.
Edwards R, Sitki-Green D, Moore D, Raab-Traub N
J Virol. 2003; 78(2):868-81.
PMID: 14694118
PMC: 368819.
DOI: 10.1128/jvi.78.2.868-881.2004.
Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro.
Bickham K, Goodman K, Paludan C, Nikiforow S, Tsang M, Steinman R
J Exp Med. 2003; 198(11):1653-63.
PMID: 14657218
PMC: 2194129.
DOI: 10.1084/jem.20030646.
Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S, Bottomly K, Miller G, Munz C
J Virol. 2003; 77(22):12088-104.
PMID: 14581546
PMC: 254269.
DOI: 10.1128/jvi.77.22.12088-12104.2003.
An efficient method for the rapid establishment of Epstein-Barr virus immortalization of human B lymphocytes.
Oh H, Oh J, Choi S, Kim S, Han W, Kim T
Cell Prolif. 2003; 36(4):191-7.
PMID: 12950388
PMC: 6495897.
DOI: 10.1046/j.1365-2184.2003.00276.x.
In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein-Barr virus (EBV) seropositive donors.
Wilson A, Hopkins J, Morgan A
Clin Exp Immunol. 2001; 126(1):101-10.
PMID: 11678905
PMC: 1906158.
DOI: 10.1046/j.1365-2249.2001.01641.x.
The immunology of Epstein-Barr virus infection.
Moss D, Burrows S, Silins S, Misko I, Khanna R
Philos Trans R Soc Lond B Biol Sci. 2001; 356(1408):475-88.
PMID: 11313006
PMC: 1088439.
DOI: 10.1098/rstb.2000.0784.
CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S, Bottomly K, Miller G
J Virol. 2001; 75(8):3740-52.
PMID: 11264363
PMC: 114865.
DOI: 10.1128/JVI.75.8.3740-3752.2001.
Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation.
Tierney R, Kirby H, Nagra J, Desmond J, Bell A, Rickinson A
J Virol. 2000; 74(22):10468-79.
PMID: 11044091
PMC: 110921.
DOI: 10.1128/jvi.74.22.10468-10479.2000.
The role of EBV in post-transplant malignancies: a review.
Hopwood P, Crawford D
J Clin Pathol. 2000; 53(4):248-54.
PMID: 10823119
PMC: 1731174.
DOI: 10.1136/jcp.53.4.248.
T-cell memory: lessons from Epstein-Barr virus infection in man.
Rickinson A, Callan M, Annels N
Philos Trans R Soc Lond B Biol Sci. 2000; 355(1395):391-400.
PMID: 10794060
PMC: 1692739.
DOI: 10.1098/rstb.2000.0579.
The Epstein-Barr virus and its association with human cancers.
Baumforth K, Young L, Flavell K, Constandinou C, Murray P
Mol Pathol. 2000; 52(6):307-22.
PMID: 10748864
PMC: 395716.
DOI: 10.1136/mp.52.6.307.
Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
OReilly R, Small T, Papadopoulos E, Lucas K, LACERDA J, Koulova L
Springer Semin Immunopathol. 1998; 20(3-4):455-91.
PMID: 9870257
DOI: 10.1007/BF00838055.